Growth hormone

Ipamorelin

Ipamorelin is a synthetic growth hormone secretagogue. Its short peptide structure contains non-standard residues and D-amino acids, which an ordinary one-letter sequence does not fully represent.

Reviewed September 2026

Residues
5. verified: 5 residues, including Aib and D-2-naphthylalanine; no substitution of canonical letters for these noncanonical residues.
Average mass
711.9 Da. verified: Reference form: Ipamorelin: Aib–His–D-2-Nal–D-Phe–Lys-NH2; free peptide moiety, without an unspecified counterion.; formula C38H49N9O5. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
pI
Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.

Reference details

Reference details
Residues5
Average mass711.9 Da
pINot established
Identity
Research areaGrowth hormone

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

Ipamorelin: Aib–His–D-2-Nal–D-Phe–Lys-NH2; free peptide moiety, without an unspecified counterion. Reference only, not a sold-lot measurement.

  • Residues: 5 (verified). 5 residues, including Aib and D-2-naphthylalanine; no substitution of canonical letters for these noncanonical residues. Residues source 1 Residues source 2
  • Average mass: 711.9 Da (verified). Reference form: Ipamorelin: Aib–His–D-2-Nal–D-Phe–Lys-NH2; free peptide moiety, without an unspecified counterion.; formula C38H49N9O5. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
  • pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1

Reference scope and linked records

Reference type: Non-standard peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: Ipamorelin. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Ipamorelin, the first selective growth hormone secretagogue. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About Ipamorelin

Identity and context

The discovery study identifies the structure as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Aib and the naphthylalanine residue require explicit chemical notation; the D configurations and terminal amide also matter. Ipamorelin is not a GHRH fragment, even though both classes can be studied using growth hormone release as an endpoint.

Reference classification

Non-standard peptide. The linked catalogue product is Ipamorelin. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Check stereochemistry, the non-standard residues and amidation against the analytical specification. Retain the distinction between free peptide content and any counterion or water contribution.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesRaun and colleagues measured hormone release in pituitary cells, rats and swine. Their selectivity claim concerns the hormone panel and experimental conditions they tested, including comparisons with other secretagogues. It should not be read as a finding that ipamorelin has no adverse effects in humans.Source context
What cannot be inferredAn animal pharmacology paper cannot establish human benefit or certify a supplier lot. A blend containing ipamorelin needs its own composition and mixture evidence; the standalone paper does not test the catalogue combination.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Ipamorelin, the first selective growth hormone secretagoguePrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.